. 2022 Jan 29;22:100. doi: 10.1186/s12879-022-07082-2

Table 3.

Factors associated with virological success at 30 months

	Univariate analysis			Multivariate analysis
	OR	95% IC	p	aOR	95% IC	p
HIV-1 DNA (< 3 vs ≥ 3 log₁₀ c/MPBMC) amongst CD4 < 500/mm³	1.74	1.20–2.50	0.003	1.87	1.28–2.71	0.001
HIV-1 DNA (< 3 vs ≥ 3 log₁₀ c/MPBMC) amongst CD4 ≥ 500/mm³	0.81	0.53–1.26	0.35	0.87	0.56–1.36	0.55
CD4 (< 500 vs ≥ 500/mm³) amongst HIV-1 DNA < 3 log₁₀ c/MPBMC	1.83	1.26–2.64	0.001	1.79	1.23–2.61	0.002
CD4 (< 500 vs ≥ 500/mm³) amongst HIV-1 DNA ≥ 3 log₁₀ c/MPBMC	0.86	0.56–1.32	0.48	0.84	0.54–1.30	0.43
HIV-1 RNA: < 5 vs ≥ 5 log10 copies/ml	1.11	0.84–1.46	0.48
Sex: male vs. female	1.24	0.88–1.75	0.22	1.04	0.72–1.51	0.81
Age: < 35 vs. ≥ 35 years	0.62	0.47–0.81	0.0005	0.63	0.47–0.83	0.001
WHO clinical stage: 1–2 vs. 3–4	0.85	0.53–1.34	0.48
IPT: received vs. not received	1.07	0.82–1.40	0.64
ART regimen
TDF/FTC + LPV/r vs TDF/FTC + EFV	0.61	0.44–0.83	0.002	0.63	0.45–0.87	0.005
TDF/FTC + AZT vs TDF/FTC + EFV	1.38	0.78–2.41	0.27	1.43	0.80–2.56	0.23

Sensitivity analysis (n = 1013)

c/MPBMC copies per million PBM; n number of patients; OR odds ratio; aOR adjusted odds ratio; IPT isoniazide preventive therapy; CI confidence interval; DNA desoxyribonucleic acid; PBMC peripheral blood mononuclear cells; RNA ribonucleique acid; LPV/r lopinavir/ritonavir; AZT azidothymidine; EFV efavirenz; TDF tenofovir; FTC emtricitabine